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ABSTRACT 
BACKGROUND 
Studies suggest an association between Bacterial Vaginosis (BV) and HIV infection; 
however, its temporal effect has not been greatly investigated. 
METHODS 
This is a secondary data analysis of a cohort study: set out to describe the association 
between BV infection and HIV acquisition. There were 750 participants enrolled in the 
primary cohort study. The main exposure, BV, was measured from a gram stain slide 
prepared from a vaginal swab. The slide was read in a laboratory qualitatively and scored 
by Nugents scoring. A score of 7 or above was considered positive for BV. The outcome 
variable (HIV) was determined by dual rapid tests and confirmed in the laboratory by a 
third generation ELISA.  Descriptive statistics was done to describe demographic 
characteristics and the prevalence of BV and STIs. HIV incidence rate was calculated. 
Kaplan Meier survival time analysis and log rank test for significance were performed.  
Cox regression (univariate and multivariate) was done to determine association of BV 
with HIV infection. 
RESULTS  
The baseline prevalence of BV was 52 %, 95 % CI; 45 – 59. There were 21 HIV 
seroconversions experienced of which 7 had BV results missing and were excluded in the 
analysis. The remaining 14 seroconversions were followed for a mean time of 0.40 of a 
year and accumulated follow up time at risk of 286 person years, this represented an HIV 
incidence rate of 4.9 per 100 person years of follow up, 95 % CI: 2.9 – 8.27. Kaplan 
Meier curves revealed a higher risk of HIV-1 acquisition among women who were BV 
positive than the women who were  BV negative. A log rank test showed that the 
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probability of seroconversion was different among the women depending on BV status, 
chi-square value 3.8, p 0.05. 
Controlling for confounding variables, seroconversion was high, but not significant, 
among BV positive women, adjusted hazard ratio 3.21; 95 % CI; 0.85-12.12, p value 
0.08. 
CONCLUSION 
This study suggests that BV increases HIV seroconversion risk though statistical 
significance was not achieved. Vaginal cleansing education, screening and treating 
women with BV could maintain normal vaginal flora and reduce their susceptibility to 
HIV. 
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CHAPTER 1:    INTRODUCTION 
1.1 BURDEN OF DISEASE HIV 
Human Immunodeficiency Virus (HIV) currently affects populations worldwide. The 
prevalence of HIV continues to grow globally and women of reproductive age experience 
consistently high rates of HIV infection. About 38 million people are infected worldwide, 
of which 29 million are in Sub-Saharan Africa [1]. It is estimated that 8 % of all adults in 
Sub-Saharan Africa are HIV infected and almost 60 % of these HIV infections occur 
among women [2]. South Africa has one of the highest HIV infection rates in Sub-
Saharan Africa and the prevalence of HIV infection has been increasing significantly 
with young people, particularly young women, are at the greatest risk [3].  It is estimated 
that 1 in 9 people are infected in South Africa with a total of 5.3 million people infected. 
The prevalence of HIV in women attending public antenatal care reached 27.9 % in 2003 
and an estimated 11.4 % of the total population is infected [4]. Determining the factors 
that increase HIV infection risk in women is significant in developing HIV infection 
prevention strategies. 
 
1.2     BURDEN OF DISEASE BACTERIAL VAGINOSIS 
 
Bacterial Vaginosis (BV) is defined as a clinical syndrome characterised by a change in 
the normal vaginal flora where, the normal lactobacilli dominated flora is replaced by 
other anaerobic organisms resulting in an increase in vaginal pH [5] and a decrease in the 
number of hydrogen peroxide producing lactobacilli. It has complex aetiology with the 
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commonly associated organisms being Gardnerella vaginalis, Mycoplasma hominis and 
Mobiluncus species. This complex aetiology limits its proper diagnosis and treatment. It 
is a common vaginal infection and the leading cause of abnormal vaginal discharge [6]. 
Women with BV present with increased vaginal discharge and on a swab taken from the 
vaginal wall a low pH and clue cells are found [6]. It is a treatable condition, however 
treatment is difficult as it is sometimes asymptomatic and because of its multicausal 
aetiology and recurrences of infection is common after treatment [7]. BV occurs in       
20-50 % of women in the general population worldwide and in Sub-Saharan Africa 
prevalence rates of 20-50 % have been reported [7]. 
The prevalence is even higher in women attending sexually transmitted infection (STI) 
clinics (40-50 %), suggesting that BV is associated with sexual activity [8]. Although 
there appears to be a clear association with sexual activity there is still debate about 
whether BV is a true STI.  
BV is diagnosed based on either clinical or laboratory based examination of a gram stain 
by Nugent score criteria. The clinical diagnosis of BV is based on an increased vaginal 
discharge, increased vaginal pH >4.5, presence of clue cells on microscopy and a positive 
whiff test. A swab of the discharge is tested with litmus paper for pH and then prepared 
in a wet mount (addition of normal saline to the sample of discharge on a 
slide).Characteristic clue cells are seen on the wet mount examined under a microscope. 
Clue cells are vaginal epithelial cells coated with bacteria. They are called clue cells 
because they provide a clue for the presence of BV. This is followed by a whiff test 
which is done by adding several drops of a base (potassium hydroxide) to a sample of the 
vaginal discharge which then releases a characteristic amine odour or fishy smell.           
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In clinical practice to make the diagnosis of BV, the following four Amsel criteria need to 
be met: 
          - An increased thin yellow homogeneous vaginal discharge, 
          - A characteristic fishy odor on wet mount by the whiff test,  
          - Loss of acidity (alkaline on litmus paper test pH >4.5),  
          - Presence of clue cells on wet mount.  
However, the clinical diagnosis may be influenced by many factors and to some extent 
depends largely on the expertise of the care provider [8]. 
 
The Nugent score diagnosis of BV is a widely used laboratory based method, it consists 
of a scoring scale system which ranges from 0-10 for assessing the vaginal flora by gram 
stain. A score of 0-3 is considered negative, 4 to 6 is regarded as intermediate and 7 or 
greater is classified positive for BV [9]. The use of gram stain with Nugent scoring is 
considered as the gold standard for diagnosing BV [10].  
 
BV has been linked with adverse public health consequences. It has been associated with 
serious obstetric complications such as spontaneous abortions, preterm labor and post 
caesarean section infections [11]. In a study to assess the role of BV on pregnancy 
complications in Durban, South Africa, it was found out that BV was found in 52 % of 
the women studied, of those who were BV positive, 46 % had poor pregnancy outcomes 
as measured by complications such as pregnancy loss and neonatal morbidity. There was 
significant difference in poor pregnancy outcome among women with BV (63 %) 
compared to women with other infections (42 %), p value 0.005 [5].  
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BV has as well been linked with the acquisition of HIV infection in women [6] and has 
been suggested as a mediator of the association between intra vaginal practices and HIV 
infection.  
Vaginal cleansing and use of intra vaginal herbs are also associated with BV infection 
[12, 13]. Other risk factors for BV include behaviours such as greater number of sexual 
partners, frequent vaginal intercourse, new sexual partner and less frequent use of 
condoms [14, 15]. These risk factors suggest that there is a link between BV and sexual 
activity and fuel the debate on whether BV is an STI or not. 
 
Besides the tremendous implications BV has on public health, there has been little 
attention to investigate the problem [11]. Treatment of vaginal discharge by syndromic 
management covers BV, however there are many organisms associated with BV and it is 
sometimes asymptomatic, therefore identifying proper treatment is difficult and the cure 
rates for BV are low ranging between 70-80 % and the recurrency rates of infection after 
treatment are high [7].  
 
1.3 STATEMENT OF PROBLEM 
 
Diseases of the reproductive tract have been reported to be associated with the sexual 
transmission of HIV infection in both males and females [16]. The focus of this 
association has been on sexually transmitted infections which are known biological risk 
factors for acquisition and transmission of HIV infection sexually. Although BV is not a 
classical STI as it is unlikely to be transmitted between partners, it is associated with 
sexual activity and the risk factors for STIs such as increased number of sexual partners. 
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BV is associated with changes in the vaginal flora, which weaken the natural defence 
mechanism present in the vagina, which may predispose women to acquisition of other 
STIs. It is therefore important to describe the risks associated with BV. The prevalences 
of BV are relatively higher than those of STIs [8]. Despite this, few prospective studies 
have been done on BV as a potential female reproductive tract infection associated with 
the risk of HIV infection acquisition [8]. The reported magnitude of association between 
BV and HIV infection is variable and depends on the definition of the exposure. It is 
therefore important to critically investigate further the association of BV and acquisition 
of HIV infection. This analysis may add further knowledge surrounding the temporal 
association of BV and HIV infection acquisition. 
 
1.4 LITERATURE REVIEW 
 
Evidence describing the association between BV and HIV infection 
 
Several cross sectional studies have shown that BV is associated with an increased risk of 
HIV prevalent infection; however few prospective studies have been conducted [8]. 
A cross sectional study was conducted in Chiang Mai, Thailand, among 144 female 
commercial sex workers to investigate the relationship between BV and HIV-1 
seropositivity in a population at high risk of sexual acquisition of HIV [17]. BV was 
detected in 33 % of the participants and HIV was detected in 43 % of the participants. BV 
was found to be significantly associated with prevalent HIV infection using the clinical 
criteria of diagnosis, odds ratio (OR) 2.7; 95 % Confidence Interval (CI), 1.3-5.0. The 
association between BV and HIV prevalence was not significant using gram stain alone 
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for the diagnosis of BV. The association was also found between abnormal vaginal flora 
and HIV prevalent infection, OR, 2.1; 95 % CI; 1.0-4.8. Multiple logistic regression was 
applied to adjust for age, number of sexual encounters per week, current condom use and 
currently having a sexually transmitted disease (STD). After adjusting, both BV and a 
history of an STD were independently and significantly associated with HIV 
seropositivity, adjusted odds ratio (AOR) for BV infection, 4.0; 95 % CI, 1.7-9.4 and 
AOR for history of an STD, 6.9; 95 % CI; 2.1-22.9.  
 
In another cross sectional study [18], involving 4718 women aged 15-59 years in rural 
Rakai District, Uganda, an HIV prevalence of 14.2 % was reported among women with 
normal vaginal flora and 26.7 % among those with severe BV. The study found an 
association between BV and prevalent HIV-1 infection among younger women, but not 
among women older than 40 years. The adjusted odds ratio for HIV-1 infection 
associated with any abnormal flora was 1.52; 95 % CI; 1.22-1.90 and 2.08; 95 % CI; 
1.48-2.94, for severe BV.  
 
Further to this, another cross sectional study conducted in North Carolina, USA, to 
investigate the association of BV with HIV infection in pregnant women, 724 women 
attending prenatal care were recruited at 24 to 29 weeks of gestation [19]. The study 
reported that HIV prevalence depended on BV status. The HIV prevalence was 0.8 %,     
1.2 % and 3.3 % among women with normal vaginal flora, intermediate vaginal flora and 
BV respectively. A multiple logistic regression model adjusting for douching gave an 
odds ratio for HIV infection associated with abnormal vaginal flora of 3.9; 95 % CI; 1.03-
14.9 and for BV the odds ratio was 3.7; 95 % CI; 1.1-13.2.  
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Besides this, a cross sectional study to determine the relationship between HIV-1 
infection and BV involving 598 women was conducted in South Africa. BV prevalence 
was 70 % and HIV prevalence was 62 % among this group, p; 0.001. It was found out 
that the odds of being HIV-1 infected was 1.5; 95 % CI; 1.3 – 1.8; p; 0.001 with a BV 
Nugent score of ≥7. BV remained independently significantly associated with HIV-1 
infection after adjusting for other factors, AOR; 2.3; 95 % CI; 1.6 – 3.3 [20]. 
 
In addition, a nested case control study was conducted in South Africa among 5110 
women enrolled in a cervical cancer trial to investigate the association of BV infection 
and susceptibility to HIV infection among South African women. The BV prevalence was   
46 % in this study, there were 86 HIV seroconversions identified in the trial and this 
represented an overall incidence rate of 2.1 per 100 person years. It was found in this 
study that diagnosis of BV on the basis of Nugent score criteria was significantly 
associated with increased risk of HIV seroconversion. In a multivariate model adjusting 
for demographic factors, STIs and other sexual behaviours the AOR was 2.01; 95 % CI; 
1.12 – 3.62 [21]. 
 
In Malawi a prospective study was conducted to determine the association of BV and 
other disturbances of the vaginal flora with HIV seroconversion among pregnant and 
postnatal women [22]. The diagnosis of BV was done based on clinical criteria only. The 
association of BV and other risk factors with HIV seroconversion were examined using 
contingency tables and multiple logistic regression analyses on antenatal data, Kaplan 
Meier proportional hazards analyses were used on postnatal data. The study involved 
1196 HIV seronegative women who were followed antenatally for a median of 3.4 
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months and 27 women seroconverted by the time of delivery. Postnatally, 97 
seroconversions were observed among 1169 seronegative women who were followed for 
a median of 2.5 years. The study reported that BV was significantly associated with 
antenatal HIV seroconversion, AOR 3.7, p, 0.04 and postnatal HIV seroconversion, ARR 
2.3, p, 0.03. 
 
Another prospective study was done in Mombasa, Kenya, to examine the relationship 
between BV and HIV infection acquisition among 657 HIV negative women commercial 
sex workers [23]. There were 68 seroconversions within 621 person years of follow up, 
with an overall incidence rate of 11 per 100 person years of follow up. BV was found to 
be significantly associated with HIV incident infections. In a multivariate Cox regression 
model after adjusting for other factors, a hazard ratio of 1.9; 95 % CI, 1.1-3.2 was 
reported for HIV-1 infection acquisition among women with BV. 
 
Similar findings were reported recently in a prospective study of HIV-1 incidence among 
women of reproductive age in Malawi. In this study, 787 HIV negative women were 
followed up for a period of 12 months. The women had subsequent HIV testing and 31 
were found HIV positive during the follow up period representing an overall incidence 
rate of 4.51; 95 % CI; 2.96 – 6.06 per 100 person years of follow up. A Cox proportional 
hazard model was used to assess the factors associated with HIV acquisition. BV was 
found to be significantly associated with incident HIV-1 infection, AHR 2.52; 95 % CI; 
1.07 – 5.94; p, 0.03 [24].  
Likewise positive findings were reported in a multi centre prospective study done in 
Zimbabwe and Uganda.  The study was conducted to evaluate the relationship between 
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BV and the risk of HIV infection acquisition. This involved 4531 HIV negative women 
aged 18 -35 years. Participants were followed for 15 to 24 months. The exposure variable 
BV was determined by gram stain and Nugent scoring. Women had subsequent HIV 
testing and there were 213 incident HIV infections. This represented an incidence rate of 
4.12 and 1.53 per 100 woman years of follow up in Zimbabwe and Uganda respectively. 
Cox proportional hazard analysis was used to investigate factors associated with HIV 
infection acquisition. The analysis was performed for the two countries combined. BV 
was found statistically significantly associated with HIV infection acquisition, AHR 1.67, 
95 % CI; 1.24-2.26[25]. 
Positive findings were also reported in a meta-analysis of published studies to assess the 
published literature on the extent to which BV may increase the risk of HIV acquisition. 
In this meta-analysis medline and other electronic data bases were systematically 
searched for eligible publications. In the studies reviewed the diagnosis of BV was based 
on clinical criteria only, Nugents score criteria only or both clinical and Nugents score 
criteria. The association of BV and incident HIV infection was analysed and evaluated. 
BV was found to be associated with an increased risk of HIV acquisition in HIV 
incidence studies, RR 1.6, 95 % CI; 1.2-2.1[26]. 
 
Studies described above that have demonstrated an association between BV and HIV 
have been summarised in the table below: 
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Table 1.1: Summary of the studies on association between BV and HIV infection 
 
Study Area Number and       
     type of 
Participants 
  Study     
  Design 
Methods of      
    BV 
Diagnosis 
      BV    
Prevalence 
    HIV 
Incidence or 
Prevalence 
Adjusted 
measure of    
association          
( 95 %  CI) 
Chiang Mai [17] (144)Commercial 
sex workers 
Cross 
sectional  
Clinical /    
 Gram stain 
     33 %     43 % OR4.0 (1.7 -9.4)  
Uganda [18] (4718) General 
population 
Cross 
sectional  
 Gram stain      55 %    26.7 % OR 2.1(1.4-2.9) 
NorthCarolina [19] (724) Pregnant 
women 
Cross 
sectional  
 Gram stain     20.9 %      03.3 % OR3.7(1.1-13.2) 
South Africa [20] (598) General 
population 
Cross 
sectional  
 Gram stain      70 %       62 %  OR 2.3(1.6- 3.2) 
South Africa [21] (5110) General 
population 
Nested case 
control  
 Gram stain       46% 2.1 per 100 
person  yrs 
OR2.01(1.1–3.6) 
Malawi [22] (1196) Pregnant 
women 
Prospective 
cohort study 
   Clinical      59 % 7.9 per 100 
person years 
OR  3.7  p; 0.04 
Kenya [23] (657) Commercial 
sex workers 
Prospective        
cohort study 
  Gram stain       36 % 11 per 100 
person years 
 HR1.9(1.1– 3.2) 
Malawi[24] (787) General 
population 
Prospective 
cohort study 
   Gram stain       68 % 4.51 per 100 
person years 
HR2.52(1.1-5.9) 
Zimbabwe/Uganda[25] (4531)General 
population 
Prospective 
cohort study 
Gram stain       50 % 4.12 per 100 
person years. 
HR1.67(1.2-2.2) 
Meta-analysis[26] 23 studies  Variable   Variable       33 %        RR 1.6 (1.2-2.1) 
 
The strengths of association between BV and HIV infection is variable, table 1.1. It 
ranges from 1.6 to 4.0 fold in the adjusted measure of association. The variation could be 
due to the different groups of women studied, numbers of women included in the study 
and different diagnostic methods used in defining the exposure and the outcome. These 
factors could result in the variation in the effect size of the association.  
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Biological Plausibility for the association between BV and HIV acquisition 
 
The vaginal flora plays an important role in protecting women from sexually transmitted 
infections including HIV infection [8]. Lactobacilli are the major inhabitants of the 
vagina; these bacteria are responsible for the production of microbial toxins including 
hydrogen peroxide. Hydrogen peroxide has been shown to inhibit the growth of micro 
organisms including Gardnerella vaginalis, Neisseria gonorrhoea (NG) and HIV [8]. 
Lactobacilli also maintain the acidity of the vagina through the production of lactic acid. 
Vaginal pH which is normally less than 4.5 is inhabitable to many organisms including 
HIV [8]. This protective nature of the vaginal flora changes in women with BV.  
 
The organisms that are associated with BV such as Gardnerella vaginalis are said to 
increase the incidence of sexual transmission of HIV by many mechanisms [27]. The 
mechanisms include vaginal microflora changes that take place during BV infection 
which lead to an increased vaginal pH and a decrease in the number of hydrogen peroxide 
producing lactobacilli. This abnormal vaginal flora causes an inflammatory response 
which leads to the recruitment of immune response cells that become the target cells for 
the HIV virus in the vagina. The inflammatory process also causes epithelial trauma, this 
allows the virus to pass the epithelial barrier more easily. These changes are believed to 
provide necessary conditions for HIV survival and replication [27].  
Summary 
Cross sectional data suggest an association between BV and prevalent HIV infection, 
although associations are varied in strength and do not provide temporal associations. 
This is supported by prospective studies that suggest an association between BV and 
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incident HIV infection, table 1.1. Many of the studies report some association between 
BV and HIV acquisition, but the exposure variable is not always ideally measured using 
the standard Nugent score criteria. The clinical diagnosis of BV can be influenced by 
many factors and depends on the expertise of the care provider [8, 16]. The evidence for 
the association between BV and HIV does seem to be conflicting if different criteria 
(Clinical or Nugents scoring) are used to define the exposure. The misclassification of the 
exposure affects the measure of effect in these studies making them hard to compare [17].  
 
1.5 STUDY OBJECTIVES 
Primary Objective 
To determine the association of BV with HIV infection acquisition among women aged 
18-35 years in Soweto. 
Secondary Objectives 
 i.   To describe the social and demographic characteristics of the study participants. 
 ii.  To describe the prevalence of BV and STIs in the study sample. 
 iii. To estimate HIV incidence in the study sample. 
1.5.1 Null Hypothesis  
BV infection is not associated with HIV infection acquisition. 
 
1.6 JUSTIFICATION FOR THE STUDY 
 
The evidence to date is mixed in strength of study design (many cross sectional studies) 
and in measurement of the exposure variable, mostly the diagnosis of BV has been based 
on clinical criteria only [17, 18, 19]. Few prospective studies in different populations 
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have been conducted, this analysis of a prospective cohort study may add evidence by the 
strength of design and by defining the exposure variable by the laboratory based Nugent 
score criteria. This analysis may also offer an opportunity to demonstrate the temporal 
relationship between BV and HIV infection. This study population is possibly more 
generalisable as it is a general population of women from a general population of South 
African women which may provide local researchers and policy makers with relevant 
local data. 
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CHAPTER 2: METHODS 
2.1 DESCRIPTION OF PRIMARY DATA 
A cohort study was conducted in Soweto between Oct 2002 and January 2005. This 
cohort study aimed to estimate HIV incidence, condom usage and retention in the cohort 
in preparation for an HIV prevention trial. Women aged 18 to 35 years were invited to 
participate and those who volunteered were screened for HIV and pregnancy. Additional 
inclusion criteria included willingness to stay in Soweto for next year and willingness to 
give consent. The exclusion criteria included women out side the age range of 18 – 35, 
HIV positive, pregnancy positive and intending to move out of Soweto within next one 
year. There were 1089 potential participants screened and 750 were enrolled. Participants 
were followed up for a maximum period of one year if they completed the study, 
however participants included in this analysis were followed for a mean period of 0.40 of 
a year. At entry, the participants were further screened for biological factors that included 
sexually transmitted diseases, Neisseria gonorrhoea (NG), Chlamydia trachomatis (CT), 
Trichomonas vaginalis (TV), syphilis, Herpes Simplex Virus 2 (HSV 2) and BV. 
 
2.2 STUDY DESIGN 
This is a secondary data analysis of a prospective cohort study which was designed to 
estimate HIV incidence and condom use. 
2.3 STUDY POPULATION 
The study population comprised HIV negative sexually active women aged 18-35 years 
in Soweto.  
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2.4 STUDY SAMPLE 
The study sample was a fixed one and consisted of all the sexually active HIV negative 
women who were enrolled in the primary cohort study. However, 683 participants were 
included in this analysis and had accumulated 286 woman years of follow up; this was 
due to the missing of BV results. These participants were followed for a mean period of 
0.40 of a year. There were 14 incident HIV infections that had BV results available and 
were included in this analysis. 
 
2.5 STUDY PROCEDURES 
 
2.5.1 Clinical Procedures 
Women were seen at the study clinic every three months. At this time HIV pre and post 
test counselling was done as were HIV rapid tests in parallel by trained nurses in the 
clinic. Structured interviews were done to collect data on potential confounders. The 
interviews gathered information on demographic factors that included age, level of 
education and social economic markers. Behavioural factor data included contraceptive 
use, condom use at last sexual act, number of sexual partners in the past three months, 
type of sexual partners and vaginal practices such as cleansing and product insertion. 
Pelvic examinations were done at baseline, six and 12 months visits where swabs were 
collected from the cervix for NG, CT, from the vaginal wall for BV and TV. Blood for 
HSV 2 and syphilis was also collected. Both syndromically diagnosed and laboratory 
diagnosed sexually transmitted infections were treated.  
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2.5.2 Laboratory Procedures 
BV was determined by laboratory based Nugent Score criteria, a gram stain scoring 
system of vaginal smears. It consists of a scoring system and ranges from 0-10. In this 
analysis a score of 7 or above was considered positive for BV. HIV infection was 
diagnosed by commercially available validated rapid HIV tests done in parallel; all 
positive and discordant tests were confirmed by a third generation Enzyme linked 
immuno-sorbent assay (ELISA).  A 10 % sample of all tests was quality controlled by 
ELISA. NG and CT were detected using Roche Amplicor® polymerase chain reaction 
(PCR) and TV sample were cultured in Diamond’s media and assessed qualitatively in 
the laboratory. Syphilis testing was done by rapid plasma reagin (RPR) and reported by 
titre and testing for HSV 2 was done by Focus Herpe Select® HSV 2 ELISA.  Summary 
of study visit and data collection procedures are presented below in table 2.1: 
 
Table 2.1: Study visit procedures 
Procedure      Visit 
 Time 0  3 months   6 months 9 months 12 months 
Demographic 
characteristics 
 
    Yes  
    
Sexual/Behavioural 
characteristics 
 
    Yes  
 
  Yes 
 
    Yes 
 
   Yes 
 
     Yes 
BV test     Yes       Yes        Yes  
HIV test     Yes    Yes     Yes     Yes       Yes 
CT,NG,HSV2,RPR     Yes         Yes            Yes 
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2.6 MEASUREMENT AND DATA SOURCES FOR VARIABLES 
2.6.1 Outcome Variable  
The outcome variable of interest was HIV infection. This was measured at three monthly 
intervals by commercially available rapid test. Testing was done in parallel by trained 
nurses in the study clinic. The tests used included Determine®, Unigold™ and Serocon. 
Tests were changed due to logistic problems with supply. Each time a new test was 
introduced a confirmation of test performance was done by a third generation ELISA. 
Throughout the study all dual positive and any discordant results were confirmed by a 
third generation ELISA in the laboratory. In addition quality control ELISA tests were 
done on the first 100 rapid tests and on a 10 % continuous quality control confirmation of 
rapid results.  
 
2.6.2 Primary Exposure Variable 
 
The primary exposure variable, BV, was also determined at baseline and at the six and 
twelve month follow up visits, gram stain was taken from the vaginal wall by a swab, 
read in the laboratory qualitatively and scored by Nugent’s scoring. For this analysis the 
exposure was considered as a categorical variable of the presence of BV by Nugent score 
of 7, greater than 7 or not. 
The potential confounding variables such as condom use at last sexual act, number of 
sexual partners last three months, behavioural and demographic factors were determined 
by using structured interviews. Inconsistent condom use has been associated with the risk 
of BV as well as the risk of HIV infection. Increased number of sexual partners is also 
associated with a high risk of BV at the same time a high risk of HIV infection. These 
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factors were therefore taken as potential confounders and have been reported in other 
studies as confounders [14, 15]. STIs were also considered as potential confounders as 
they are known biological risk factors of HIV infection transmission [16], they were also 
considered for potential effect modification on the association of BV and HIV acquisition 
as they are also independently associated with the risk of HIV infection. 
 Vaginal cleansing alters the vaginal normal flora and is associated with an increased risk 
of BV [12, 13]. Vaginal cleansing, STIs and BV could concurrently influence the risk of 
HIV infection.  Multivariate analysis was done to control for possible confounding effect 
of these factors. An assessment was also carried out to check for possible effect 
modification of STIs and vaginal cleansing on the association of BV and HIV infection 
acquisition.  
 
2.7 DATA PROCESSING METHODS AND DATA ANALYSIS PLAN 
2.7.1 Data Cleaning and Dataset Set up 
 
Data cleaning and all the data analysis was done using STATA® version 10. The primary 
data sets were stored in a data base in three separate files. The required variables were 
extracted from each of the three files. All the participants screened without an enrolment 
number were dropped to remain with the enrolled participants only. Standard data 
cleaning procedures to identify values on variables was carried out by conducting checks 
on all the extracted variables to determine the extent of missing values and all the 
variable values entered as 9, 98 and 99 for example were set as missing. Then the data 
files were merged using participants’ unique identity numbers to have one data set file for 
this analysis. Participants with missing BV results were excluded from the analysis. 
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2.7.2 Data Coding 
To facilitate analysis some of the variables in the original data set were recoded. The 
variables for example, type of house, were recoded to include formal and informal type of 
houses only. The education status of the participants was recoded to have those with no 
schooling at all, those with less than 12 years of schooling and those with 12 years or 
more of schooling. Marital status was also recoded to include two groups, those living 
(cohabiting) with their sexual partners and those not living (not cohabiting) with their 
sexual partners. 
 
2.7.3 Descriptive Statistics 
 
The analysis was done using STATA® version 10 and all the variable values and 
measures of effect have been reported with 95 % confidence intervals and p values where 
appropriate. The descriptive frequency of social demographic and behavioural 
characteristics of study participants were calculated using contingency tables. The 
baseline prevalence of BV and STIs in the sample was also calculated using contingency 
tables. The chi square test of significance was conducted on categorical data and a 
Student’s T test on continuous variables to compare the baseline characteristics of women 
who were positive for BV and those who were negative.  
 
2.7.4 Analytical Statistics 
To investigate the association of BV and HIV infection acquisition the following analysis 
was done: 
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HIV incidence was calculated; the incidence was estimated as the number of 
seroconversions and is expressed per 100 person years of follow up. Duration of follow 
up time at risk was defined as the mid point time from enrolment to time of 
seroconversion for those who seroconverted and from time of enrolment to last time of 
follow up or last HIV negative result for those who remained negative.  
The risk factors for seroconversion analysed in the models include age, income, 
education status, marital status, number of sexual partners last 3 months, condom use at 
last sexual act, vaginal cleansing, contraception use, BV, Nugent score, NG, CT, HSV 2, 
TV and syphilis. Kaplan Meier survival time analysis was performed comparing time to 
event of exposed to unexposed and log rank test for significance in the time to event were 
calculated. A univariate Cox regression analysis to determine whether exposure to BV is 
associated with HIV infection was done. 
The variables were then included in a multivariate Cox regression analysis with a set p 
value of ≤ 0.1 as a point of entry to include potential confounders. Product terms of 
vaginal cleansing and BV, STI and BV were run respectively to check for possible effect 
modification of these factors on the association between BV and HIV infection. 
 
2.7.5 Ethical Considerations 
 
The primary prospective cohort study has ethical clearance from the Human Research 
Ethics Committee (HREC); reference number M02-01-09. The participants were 
consented and signed an informed consent prior to study participation. Participant names 
were not used on all data that was collected on report forms and laboratory result forms. 
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The study participants were told the potential risks and benefits of the study prior to their 
participation in the study. They were free to or not to participate and had the freedom to 
withdraw at any time. Treatment for any STIs was offered freely to the participants in the 
due course of the study. The study protocol for secondary data analysis was assessed by 
the University of the Witwatersrand Human Research Ethics committee for ethical review 
and clearance. It was approved and its ethics clearance number is M080984. Data 
analysis was done only after the approval of the protocol by the ethics committee. 
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CHAPTER 3:   RESULTS 
This chapter presents the study findings. The results are based on the objectives of the 
study and cover the social demographic characteristics of the participants, the prevalence 
of BV and STIs, the estimated HIV incidence in the study sample and the evaluation of 
the association of BV and risk of HIV infection acquisition. 
3.1     SOCIAL DEMOGRAPHIC AND BEHAVIOURAL CHARACTERISTICS     
         OF THE PARTICIPANTS 
There were 1089 potential participants screened and 750 were enrolled in a primary 
cohort study following HIV negative results. The participants were all from Soweto 
Township and had comparable baseline characteristics. The median age of the 
participants was 23, (inter quartile range of 20 – 28 years). The majority of the 
participants had 12 years or more of schooling (48 %), followed by those who had less 
than 12 years of schooling (43 %) and then those who did not go to school (9 %). They 
were mainly living in formal type of houses (88 %) and more than half (66 %) of the 
participants had a source of income. A large proportion of the participants (79 %) 
reported ever having used a condom, and only 7 % of the participants reported to have 
been practicing vaginal cleansing. The majority of the participants (82 %) were not living 
with a sexual partner and only 8 % of the women reported having more than one sexual 
partner. The participants made use of contraception with 57 % using hormonal 
contraception (injectable and oral contraception) and 43 % were on non hormonal 
contraception (condoms and natural methods).  The primary cohort study participant flow 
from screening visit up to last follow up visit is outlined below:      
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Table 3.1: Primary study participant flow chart 
 
There were 21 seroconversions experienced in the entire study. In total there were 236 
participants excluded during the course of the study. These included 109 participants who 
were found pregnant during the study and 127 participants who were lost to follow up. 
This analysis involved 14 HIV seroconversions among 683 participants who had BV 
      Visit Type   (n) Participants     (n) Participants    
    attained end point 
(n) Participants end   
            visit 
Screening              
          1089 
      264-pregnant 
       39 –HIV positive 
       36-not willing 
 
            750 
Visit 0 (Baseline)                
            750 
       
       
      
 
            750 
Follow up Visit 1                
             750 
        13-pregnant 
         5-HIV positive          
        99-lost to follow up 
 
            633 
Follow up Visit 2                
             633 
        21-pregnant 
          7-HIV positive      
        15-lost to follow up 
         
            590 
Follow up Visit 3              
             590 
        34-pregnant 
          5-HIV positive 
        11-lost to follow up 
 
            540 
Follow up Visit 4                 
             540 
        41-pregnant 
          4-HIV positive 
          2-lost to follow up 
          
            538 
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results and had accumulated 286 person years of follow up depending on their specific 
time of exposure. 
3.2     DESCRIPTION OF THE STUDY PARTICIPANTS AND BASELINE BV      
          PREVALENCE 
The table below describes the baseline characteristics and baseline BV prevalences of the 
study participants within the specific groups. 
Table 3.2: Description of Study Participants and BV Baseline Prevalence  
 
 
Characteristic     n (%)    BV at Baseline     
          n (%) 
  No BV at Baseline    
             n (%) 
    p     
Value 
Education(n=750) 
  No Schooling 
<12 yrs School 
>=12 yrs School 
  
    68 (9) 
  320(43) 
  362(48) 
 
         32  (8) 
       171 (45) 
       177 (47) 
 
             32  (9) 
           139 (40) 
           175 (51) 
 
 
 0.42 
House(n=750) 
 Formal 
 Informal 
 
 662(88) 
   88(12) 
 
       334 (88) 
         46 (12) 
 
           310 (90) 
             36 (10) 
 
 
 0.47 
Income(n=748) 
 Yes 
  No  
 
 491(66) 
 257(34) 
 
       248 (65) 
       132 (35) 
 
           230 (67) 
           114 (33) 
  
 0.65 
Condom Use last sex 
act(n=750) 
 Yes 
  No  
 
  
594(79) 
158(21) 
 
       
        307 (81) 
          73 (19) 
 
             
           268 (77) 
             78 (23) 
 
  
 0.26 
Ever vaginal cleansed 
(n=750) 
 Yes 
  No  
 
   51(07) 
 699(93) 
 
         29  (08) 
       351  (92) 
 
              22 (06) 
            324 (94) 
 
  0.5 
Number of Sexual 
Partners last 3mths 
(n=691) 
One 
More than one 
 
  
 
638(92) 
  53(08) 
 
        
 
       323  (91) 
         32  (09) 
 
             
 
            297(94) 
              20(06) 
 
   
 
 0.19 
MaritalStatus(n=750) 
Cohabiting 
Not Cohabiting 
 
 138(18) 
 612(82) 
 
         71  (19) 
        309 (81) 
 
              61(18) 
            285(82) 
 
  0.71 
Contraception(n=750) 
Hormonal 
Non Hormonal 
 
 425(57) 
 325(43) 
 
        218  (57) 
        162  (43) 
 
            194 (56) 
            152 (44) 
 
  0.72 
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The women who tested positive for BV at baseline were not statistically different from 
the women who tested negative for BV within the specific participants’ characteristics. 
The overall baseline prevalence of BV in the study was 52 %, 95 % CI; 45 – 59. There 
does not seem to be any differences between those participants who had their BV results 
and those who had BV results missing, suggesting that BV results were missing at 
random. Most common reason for missing BV results was that samples were not taken at 
the time of the clinical visit because the participant was menstruating. 
 
3.3 BASELINE STI PREVALENCE OF THE STUDY PARTICIPANTS 
 
Herpes Simplex Virus 2 had the highest prevalence in the study sample (54 %). This was 
followed by CT, TV, syphilis and NG with the prevalence of 12 %, 4 %, 2 % and 2 % 
respectively, as shown in the table below: 
Table 3.3: Description of Baseline STI Prevalence 
   
   Sexually Transmitted Infections 
                     
                            n (%) 
 
 
N.gonorrhoea (n =685) 
 
                           15 (2) 
 
C.trachomatis (n = 688) 
 
                           83(12)                    
 
T. vaginalis (n = 737) 
 
                          31  (4) 
 
Herpes Simplex Virus 2(n = 733) 
 
                         393(54) 
 
Syphilis (n = 747) 
 
                          18  (2) 
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3.4 HIV INCIDENCE AND SURVIVAL TIME OF THE WOMEN 
 
There were 683 participants included in the final analysis on HIV incidence and the 
association between BV and HIV infection acquisition. Participants were followed for a 
possible maximum period of one year and were followed for a mean period of time of 
0.40 of a year. This accumulated 286 person years of follow up time at risk for the 
participants who had BV results. There were 21 HIV seroconversions experienced 
throughout the follow up period of which 7 had BV results missing and were excluded 
from this analysis. The remaining 14 incident infections represents a crude HIV incidence 
rate of 4.9 per 100 person years of follow up, 95 % CI: 2.9 – 8.27. There were 4 HIV 
seroconversions among the women who were BV negative within a total follow up period 
of 161 person years. This represented an HIV incidence rate of 2.49 per 100 person years 
of follow up, 95 % CI: 0.93 – 6.63. Likewise, among the women who were BV positive 
10 HIV seroconversions were experienced within 125 person years of follow up. The 
HIV incidence rate among this group was 8.0 per 100 person years of follow up, 95 % CI: 
4.3 – 14.87.  
Survival Time analysis 
The Kaplan Meier survival curves for HIV seroconversion comparing women who had 
BV to those who did not was performed and is shown below: 
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Fig 1: HIV sero conversion Rate by BV status. 
A higher risk of HIV-1 acquisition was present among women who tested positive for BV 
than the women who tested negative  for BV at every point through out the follow up 
period (Fig 1). A Log rank test was performed with a chi-square value of 3.8 and p value 
0.05, meaning that the probability of seroconversion was different among the women 
depending on BV status. 
 
3.5 ASSOCIATION OF BV WITH HIV SEROCONVERSION 
 
The following factors were investigated for possible association with the risk of HIV 
seroconversion, BV, education level, age, income, contraception, marital status, number 
of sexual partners last three months, vaginal cleansing, BV Nugent score, NG, CT, and 
HSV 2,  however, most of these did not meet the criteria for retention into the multivariate 
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model. Vaginal cleansing is also associated with BV and may concurrently increase the 
risk of HIV-1 seroconversion. To assess this synergistic effect, an interaction term of BV 
and vaginal cleansing was run and it revealed no effect modification on the risk of HIV-1 
seroconversion between BV and vaginal cleansing.  An interaction term was also run for 
STIs and BV and there was no effect modification observed. 
The table below presents findings for univariate and multivariate Cox regression analysis 
to determine the association of BV with the risk of HIV-1 acquisition. The other 
covariates were also assessed.  In the univariate out put, only sexually transmitted 
infections (NG and CT) had an association with the risk of HIV seroconversion which 
was statistically significant. The rest of the reported associations did not attain the 
statistical significance.  
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Table 3.4: Univariate and Multivariate Cox Analysis 
 
                            Cox Univariate Analysis     Cox  Multivariate Analysis 
Variable  HR (95 % CI)  P value      HR (95 % CI)       P value 
BV 
   No 
   Yes  
 
           1 
2.97(0.93-9.52) 
 
 
   0.07 
 
 
     3.21(0.85-12.12) 
  
 
        0.08     
Nugent Score 1.20(0.98-1.49)    0.08   
Age 1.02(0.94-1.11)    0.56   
Sex Partners 
Last 3months 
 
1.94 (0.44-8.44) 
    
   0.37 
  
Education  
 No schooling 
  < 12 yrs Sch 
  ≥ 12 yrs sch 
 
            1 
2.28(0.29-17.7) 
1.58(0.2-12.52) 
 
 
   0.42 
   0.66 
  
Income 
  No 
  Yes  
 
            1 
0.48(0.20-1.12) 
 
 
   0.09 
  
Ever vaginal 
cleansed 
  No 
  Yes  
 
  
            1 
1.95(0.26-14.6) 
 
 
 
   0.51 
  
Marital Status 
Cohabiting 
Not Cohabiting 
 
            1 
1.33(0.39-4.52) 
 
 
   0.64 
  
Contraception 
   Non hormonal     
   Hormonal 
 
           1 
1.57(0.63-3.88) 
 
 
   0.33 
  
Gonorrhoea 
   No 
   Yes  
 
            1 
7.4(1.61-33.67) 
 
 
   0.01 
 
 
    4.9(1.06-23.4) 
   
 
          0.04 
Chlamydia 
   No  
   Yes  
 
            1 
3.45(1.04-11.5) 
 
 
   0.04 
  
HSV2 
  No 
  Yes  
 
            1 
2.22(0.70-7.09) 
 
 
   0.17 
  
 
3.5.1 Univariate Results 
BV infection was associated with higher risk of HIV-1 infection acquisition though 
statistical significance was not achieved, women who were BV positive had an increased 
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risk of acquiring HIV-1 infection, HR, 2.97; 95 % CI, 0.93-9.52, p, 0.07 where as the risk 
of HIV-1 seroconversion for BV Nugent score was 1.2; 95 % CI: 0.98-1.49, p; 0.08, table 
3.4. This means that for every one unit increase in Nugent score, the risk of HIV 
seroconversion increases by 20 %. 
 
The results are suggestive of a decreasing trend in the risk of HIV seroconversion as the 
education level of the participants increased though statistical significance was not 
achieved, with the women who had 12 years or more of education being less likely to 
seroconvert than women with less than 12 years of education, HR, 1.58; 95 % CI; 0.2-
12.52, p, 0.66, and 2.28; 95 % CI; 0.29-17.7, p, 0.42 respectively. Similarly participants 
age had no statistical significance on the risk of HIV seroconversion despite its slight 
positive trend towards an association, HR, 1.02; 95 % CI; 0.94 - 1.11, p, 0.56. This means 
that with an increase of the womens’age by one, there is an increase in the risk of HIV 
seroconversion by 2 %. Likewise women who had a source of income were 52 % less 
likely to seroconvert than the women who had no source of income, though statistical 
significance was not achieved either, HR, 0.48; 95 % CI; 0.20-1.12, p, 0.09.  
 
The results show that vaginal cleansing may be associated with an increased risk of   
HIV-1 acquisition, hazard ratio, 1.95; 95 % CI; 0.26 – 14.6, p, 0.51. The women who 
practised vaginal cleansing were more likely to seroconvert than those who did not.    
Results also show that participants number of sexual partners could be associated with 
increased risk of HIV-1 seroconversion, HR; 1.94; 95 % CI; 0.44 – 8.44, P, 0.37 and that 
not  living with a sexual partner may be associated with an increased risk of HIV-1 
seroconversion, HR, 1.33; 95 % CI, 0.39-4.52; p, 0.64. 
 
 
31
Though statistical significance was not attained, women who were on hormonal 
contraception were more likely to seroconvert than women on non hormonal 
contraception, HR, 1.57; 95 % CI; 0.63 – 3.88, p; 0.33.  
The women who had NG infection had a statistically significantly higher risk of HIV-1 
seroconversion, HR, 7.4; 95 % CI, 1.61-33.67, p, 0.01.  Similarly, CT infection was also 
associated with a statistically significantly increased risk of acquiring HIV infection, HR, 
3.45; 95 % CI; 1.04 – 11.5, p, 0.04. The women who were positive for HSV2 were 2.22 
times, 95 % CI, 0.70-7.09, p, 0.17, more likely to seroconvert than the women who had 
no HSV 2; however statistical significance was not achieved in this case.  
 
3.5.2 Multivariate Results 
 
The variables gained entry into the multivariate model if they had a p of ≤ 0.1 in the 
univariate model, these included BV, BV Nugent score, income, NG and CT. Variables 
were retained in the multivariate model if they maintained a p of ≤ 0.1. The final model 
contained the variables BV and gonorrhoea. Therefore, after adjusting for other factors, 
BV was associated with an increased risk of HIV seroconversion, HR, 3.21; 95 % CI; 
0.85 – 12.12, p, 0.08.   
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CHAPTER 4:    DISCUSSION, RECOMMENDATIONS 
                            & CONCLUSION 
This study produced no significant findings; however the findings suggest that BV is 
associated with an increased risk of HIV infection acquisition in women.  
The study revealed a high baseline BV prevalence among women aged 18 – 35 years in 
Soweto. The BV baseline prevalence was 52 %; 95 % CI; 45-59 a finding which is 
similar to that of other studies in South Africa and many settings [5, 7, 8, 21]. The women 
who were BV positive were not statistically different from the women who were BV 
negative in any baseline demographic characteristics. This may be due to the fact that the 
women volunteered to participate in the primary study as such this made them to be 
similar in many aspects. The homogeneity could also be a result of the study population 
which only comprised women from a local South African setting in Soweto. 
 
The baseline STI prevalences in this study are similar to those reported in other studies 
[21, 22]. The results also shows a high HIV incidence rate of 4.9 per 100 person years of 
follow up, 95 % CI; 2.9 – 8.27. This is relatively higher if compared to HIV incidence 
estimates reported in other areas in South Africa [28]. The majority of women in this 
study were not living with their sexual partners and had an increased risk of HIV 
seroconversion, HR, 1.33, 95 % CI; 0.39 – 4.52, p, 0.64.  In a study to measure HIV 
incidence in a rural area of South Africa in KwaZulu Natal, an HIV incidence rate of 3.8 
per 100 person years of follow up, 95 % CI; 3.2 – 4.6 [28] was reported.  Similarly, the 
HIV risk of seroconversion in the KwaZulu Natal study was twice as high among women 
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who were unmarried but had a sexual partner than those who were married. Not living 
with a sexual partner, may have increased the risk of HIV seroconversion among women 
in this analysis as they may have been more likely to engage in risky sexual behaviours 
and have frequent sexual partner changes as may their partners, these factors may have 
increased the risk of BV infection among the women as well. High rates of infection in 
this case may therefore be attributed to high rates of partner change among the women. 
  
A similar HIV incidence rate of 4.51 per 100 person years of follow up, 95 % CI; 2.96 – 
6.06 was reported in Malawi among women of reproductive age [24]. It was reported in 
the study that BV was a strong predictor of HIV infection acquisition. Likewise the 
results of this analysis, show the same pattern that women who were BV positive were 
more likely to seroconvert than the women who were BV negative, HR, 2.97, 95 % CI; 
0.93-9.52, p, 0.07. BV may affect HIV-1 acquisition in many ways; these include vaginal 
pH changes, changes on the integrity of the vaginal epithelium and changes in the genital 
microflora that occur with BV [25]. These changes may increase the women’s risk of 
HIV infection acquisition.  
 
After adjusting for demographic factors, other STIs and sexual behaviours, it was 
observed that BV was associated with the risk of HIV seroconversion, adjusted hazard 
ratio 3.21, 95 % CI; 0.85-12.12, p value 0.08. This suggest that BV is associated with a 
higher risk of HIV-1 infection acquisition with the BV positive women being 3 times 
more likely to seroconvert than the women who were BV negative within the follow up 
period. However, the confidence interval is wide (0.85 – 12.12), meaning that the 
population value may be anywhere in between 0.85 and 12.12. In addition the confidence 
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interval includes one and the p value is greater than 0.05, implying that the association is 
not statistically significant. The reasons for this wide confidence interval include sample 
size which was small and few incident infections that were included in the analysis due to 
the exclusion of 7 incident infections. 
 
These results of BV being associated with an increased risk of HIV infection acquisition 
are also reflected in the findings of other studies conducted in different settings on the 
temporal effect of the association of BV and HIV infection. 
 
A prospective study conducted in Malawi reported a significant association of BV with 
the risk of HIV seroconversion, an adjusted risk ratio for BV of 2.3, p; 0.03 was reported 
[22]. A similar pattern was also found in another prospective study done in Mombasa, 
Kenya [23], BV was found to be significantly associated with HIV incident infections 
with an  adjusted hazard ratio of 1.9, 95 % CI; 1.1-3.2.  Likewise  findings obtained 
recently in a prospective study of HIV-1 incidence among women of reproductive age in 
Malawi, an association between BV and HIV infection acquisition was observed, 
adjusted hazard ratio, 2.52, 95 % CI; 1.07 – 5.94; p; 0.03 [24]. Positive findings were also 
obtained in a multi centre prospective study conducted in Zimbabwe and Uganda, BV 
was found statistically significantly associated with HIV infection acquisition, AHR 1.67, 
95 % CI; 1.24-2.26[25]. Similarly, positive findings were reported in a meta-analysis to 
assess the extent to which BV may increase the risk of HIV acquisition. BV was 
statistically significantly associated with HIV infection acquisition, ARR 1.6, 95 % CI; 
1.2-2.1[26]. 
 
 
35
Statistical significance was not achieved in this analysis possibly due to a small number 
of the BV positive women who seroconverted within a total person time of follow up of 
125 person years whereas the women who were BV negative who seroconverted were 
followed up for a total person time of 161 person years. Lack of statistical significance 
could also be explained as a result of the potential bias introduced by the exclusion of the 
7 HIV seroconversions in this analysis which had no BV results.  If this study is 
compared to the Malawi study [24] which had a similar sample size, but had far more 
HIV seroconversions analysed than those analysed in this analysis thereby achieving 
statistical significance. The effect size of the association of BV with the risk of HIV 
seroconversion is also relatively higher in this analysis than that reported in many studies 
[22, 23, 24, 25].  
This could result from a wide range of factors; firstly the prevalence of BV in the study 
participants though comparable to other settings was relatively higher. In a high BV 
prevalence setting it may be difficult to detect differences in seroconversion rates. 
Besides this, most of the participants too were not living with a sexual partner; this could 
be associated with frequent change of new sexual partners and hence increased risk of 
BV and STIs among the women and hence increased risk of HIV infection. These factors 
may have inflated the effect size of BV with the risk of HIV seroconversion.  
 
The risk described in this study supports the biological plausibility of the factors 
described in the relationship of BV and HIV-1 acquisition. Many factors may lead to 
HIV-1 infection acquisition in women with BV. The normal vaginal flora which plays a 
protective role in women’s susceptibility to sexually transmitted infections is disturbed; 
there is depletion of lactobacilli which may limit production of hydrogen peroxide and 
 
 
36
other antibacterial activities which are protective against potentially pathogenic 
organisms such as those that cause sexually transmitted infections and possibly HIV. The 
low vaginal pH has been suggested to inhibit CD4 lymphocyte activation and reduce HIV 
target cells in the vagina [22]. In this case lack of lactic acid produced by lactobacilli 
could lead to an elevated pH which could be conducive to the growth and survival of the 
virus. BV also increases HIV-1 acquisition by changing cervicovaginal epithelial 
integrity and permeability and it is also suggested that it causes an inflammatory reaction 
in the female genital tract [25]. With these mechanisms present in BV positive women 
their risk of HIV infection may be increased. 
 
4.1 STRENGTHS OF THE STUDY 
  
This study is a cohort study which allows the exposure (BV) to have been measured prior 
to the outcome (HIV) and its temporal sequence adds to the growing knowledge of BV 
being associated with the risk of HIV infection acquisition among women. The primary 
exposure in the study was defined by laboratory Nugent score criteria. This criterion is 
classified as the gold standard for the diagnosis of BV [10]. This reduced measurement 
error and misclassification of the exposure. 
The definition of the outcome too was confirmed by ELISA which has a high specificity 
[30]. This made it possible to precisely classify participants who truly had the HIV virus 
as outcomes, this as well reduced misclassification of the outcome. The primary cohort 
study too had a good follow up and retention rate, above 80 %, and in addition, the data 
used in this analysis is local South African data from the general population. 
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4.2 LIMITATIONS OF THE STUDY 
The interpretation of the findings in this study is subject to important limitations:  
4.2.1 Volunteers 
The participants in the primary cohort study volunteered to take part as such they may 
differ with those who did not take part. This may have an influence on the 
generalizability of these findings due to selection bias this may have introduced.  
4.2.2 Information Bias 
Although interviewers were trained to conduct structured interviews, interviews can 
introduce information bias, and there is a possibility that participants may have hidden 
some pertinent information for this study.  
4.2.3 Secondary Data Analysis 
This study is a secondary data analysis of a primary cohort study that was designed for 
the evaluation of another research question and not the association between BV and the 
risk of HIV infection acquisition, therefore BV was not specifically taken as an exposure 
of interest and some information in this case was not available which was pertinent for 
the evaluation of this research question. For example, BV results for seven participants 
who seroconverted were missing and these were not included in the analysis. This may 
have biased the study findings. 
4.2.4 Few number of end Points analysed 
The number of HIV seroconversions analysed was low due to the exclusion of those that 
had no BV results; this made it difficult to find the statistical significance of the 
association of BV and HIV infection acquisition and made the confidence intervals wider.  
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4.2.5 Misclassification of end Points 
In addition the confirmation of HIV status at baseline did not include PCR testing for the 
presence of virus prior to an antibody response, this may have misclassified already HIV 
positive women at baseline as HIV negative, thereby inflating seroconversion rate in the 
study. 
4.2.6 Loss to Follow up 
 Though the retention rate was high, above 80% in the primary study, the women who 
were lost to follow up may differ considerably to the other participants in the study, 
thereby affecting the generalizability of the findings of the study. In addition some 
outcomes may have been missed among women who did not complete the follow up.  
4.2.7   Un measured confounding and Limitation of Cox regression model  
Further to this, unmeasured confounding may have overestimated the association between 
BV and HIV seroconversion. Although a range of confounding variables were adjusted 
for, including sexual behaviours and different STIs, the possibility of residual 
confounding cannot be ruled out that may have contributed to the observed adjusted 
hazard ratio. In addition to this, Cox regression model could not be performed on the 
variable ever used condom because there was one participant who seroconverted who 
was not using condoms as such the data could not converge. Similarly, regression could 
not be done on syphilis and TV because there was one participant who seroconverted 
who had syphilis and there was no participant who seroconverted who tested positive for 
TV.  
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4.3       RECOMMENDATIONS 
  
Based on the limitations of the study, the following recommendations are proposed. 
Another study designed specifically to answer the question of whether BV is associated 
with HIV-1 acquisition be conducted, with an adequate sample size and powered to 
detect a difference in the number of seroconversions between the two groups. The study 
should take BV as the primary exposure of interest and gather all the information 
regarding BV results on all the participants. A study describing the association between 
the treatment of BV and HIV-1 infection acquisition would also be of interest. 
 
4.4 CONCLUSION  
 
In summary BV is an ongoing burden among women, evident with its high prevalence in 
this cohort. This study contributes to the knowledge that BV is associated with HIV 
infection acquisition, the women who were BV positive were more likely to seroconvert 
than the women who were BV negative, although not significant. The vaginal discharge 
caused by BV may interrupt the lives of many women so improved care should be 
provided to screen and treat BV in the primary health care setting. Women should also be 
exposed to education on vaginal cleansing as this predisposes them to BV. 
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